Single-dose ceftriaxone kinetics in functionally anephric patients. 1983

K Stoeckel, and P J McNamara, and G Hoppe-Seyler, and A Blumberg, and E Keller

The disposition profile of ceftriaxone was studied in 12 functionally anephric patients (creatinine clearance less than 10 ml/min) who received bolus injections of 150, 500, and 1500 mg IV in a noncrossover fashion. As in healthy subjects, the kinetics in uremic patients were nonlinear for total (bound plus unbound) and linear for free (unbound) drug. The plasma protein binding was reduced due to a decreased association constant, resulting in a doubling of the free fraction in plasma. Ten of 12 patients showed nonrenal clearance values of unbound drug (ClFNR) identical to those in healthy adults and only minor increases in their biologic t1/2(beta) compared to normal (12 and 8 hr). These patients would require no dose adjustments in their dosing regimen. Two of the patients exhibited decreased ClFNR values and increased t1/2(alpha) of 20 and 34 hr. Anephric patients with impaired nonrenal elimination would require minor dose adjustments.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D002443 Ceftriaxone A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears. Benaxona,Cefatriaxone,Cefaxona,Ceftrex,Ceftriaxon,Ceftriaxon Curamed,Ceftriaxon Hexal,Ceftriaxona Andreu,Ceftriaxona LDP Torlan,Ceftriaxone Irex,Ceftriaxone Sodium,Ceftriaxone Sodium, Anhydrous,Ceftriaxone, Disodium Salt,Ceftriaxone, Disodium Salt, Hemiheptahydrate,Lendacin,Longacef,Longaceph,Ro 13-9904,Ro-13-9904,Ro13-9904,Rocefalin,Rocefin,Rocephin,Rocephine,Tacex,Terbac,Anhydrous Ceftriaxone Sodium,Ro 13 9904,Ro 139904,Ro13 9904,Ro139904
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic

Related Publications

K Stoeckel, and P J McNamara, and G Hoppe-Seyler, and A Blumberg, and E Keller
May 1985, Clinical pharmacology and therapeutics,
K Stoeckel, and P J McNamara, and G Hoppe-Seyler, and A Blumberg, and E Keller
July 2000, Journal of clinical gastroenterology,
K Stoeckel, and P J McNamara, and G Hoppe-Seyler, and A Blumberg, and E Keller
October 1978, Antimicrobial agents and chemotherapy,
K Stoeckel, and P J McNamara, and G Hoppe-Seyler, and A Blumberg, and E Keller
April 1970, Journal of pharmaceutical sciences,
K Stoeckel, and P J McNamara, and G Hoppe-Seyler, and A Blumberg, and E Keller
June 1974, Clinical pharmacology and therapeutics,
K Stoeckel, and P J McNamara, and G Hoppe-Seyler, and A Blumberg, and E Keller
January 1987, Antimicrobial agents and chemotherapy,
K Stoeckel, and P J McNamara, and G Hoppe-Seyler, and A Blumberg, and E Keller
January 1990, Minerva chirurgica,
K Stoeckel, and P J McNamara, and G Hoppe-Seyler, and A Blumberg, and E Keller
November 1974, The Journal of clinical investigation,
K Stoeckel, and P J McNamara, and G Hoppe-Seyler, and A Blumberg, and E Keller
August 1986, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
K Stoeckel, and P J McNamara, and G Hoppe-Seyler, and A Blumberg, and E Keller
May 1990, Journal of clinical pharmacology,
Copied contents to your clipboard!